AstraZeneca’s Real-World Study on Tezepelumab: Implications for Severe Asthma Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca has launched a real-world study titled Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia. The study aims to evaluate the efficacy of Tezepelumab in treating severe asthma across different phenotypes in Russia, focusing on patient-reported outcomes.

The intervention being tested is Tezepelumab, an add-on maintenance treatment for severe asthma. It is designed to improve symptom relief and reduce asthma exacerbations in patients.

This observational study is non-interventional, meaning it does not alter standard clinical practices. It involves collecting data from patients who are already receiving Tezepelumab as part of their regular treatment regimen. The study will track patient outcomes over a 52-week period.

The study began on September 10, 2024, with an estimated completion date in 2026. The last update was submitted on August 11, 2025. These dates are crucial for investors to gauge the study’s progress and potential impact on AstraZeneca’s product pipeline.

The study’s findings could influence AstraZeneca’s stock performance by demonstrating Tezepelumab’s effectiveness, potentially increasing market share in the asthma treatment sector. This could also affect investor sentiment positively, especially if the results show significant improvements over existing treatments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.